Primary analysis of ProTEct-MS, a randomised, placebocontrolled, phase 2 study of temelimab for the prevention of neurodegenerationin rituximab-treated patients with relapsing multiple sclerosis

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2022
This article has no abstract
Epistemonikos ID: 8373174cf2e916a471f4eea4fe1a494adb48be62
First added on: Apr 30, 2026